| 英文别名 |
3P63ZTE3OY;SB17246;3-Pyridinecarboxamide, N-(3-((1S)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-;Unii-3P63zte3OY;Seralutinib;GTPL10618;(S)-N-(3-(1-((6-(3,4-Dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide;SERALUTINIB [INN];N-(3-((1S)-1-((6-(3,4-DIMETHOXYPHENYL)-2-PYRAZINYL)AMINO)ETHYL)PHENYL)-5-METHYL-3-PYRIDINECARBOXAMIDE;3-Pyridinecarboxamide, N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)-2-pyrazinyl]amino]ethyl]phenyl]-5-methyl-;EX-A5138;CHEMBL4650333;Seralutinib [USAN];AKOS040759567;PK10571;SCHEMBL17324860;SERALUTINIB [WHO-DD];1619931-27-9;AT11371;PK-10571;GB-002;CS-0116463;N-(3-((1S)-1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylpyridine-3-carboxamide;HY-109190;structure 2a (WO2014110200A1);D12002;Gb002;WHO 11243;Seralutinib (USAN/INN);structure 2a [WO2014110200A1];MS-28681;N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide;N-{3-[(1S)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide |